stockrowBio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) Gross margin
Bio-Rad Laboratories, Inc.'s gross margin over the twelve months to 30 September 2026 was 51.3%, down 0.6 percentage points from fiscal 2025 (51.9%). Over the past ten years it has ranged from 51.9% (fiscal 2025) to 56.5% (fiscal 2020) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of 57.8% and in line with the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 51.9% | (1.86) |
| FY2024 | 53.7% | 0.31 |
| FY2023 | 53.4% | (2.51) |
| FY2022 | 55.9% | (0.12) |
| FY2021 | 56.1% | (0.43) |
| FY2020 | 56.5% | 2.10 |
| FY2019 | 54.4% | 0.95 |
| FY2018 | 53.4% | (1.55) |
| FY2017 | 55.0% | (0.07) |
| FY2016 | 55.1% | (0.49) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 50.1% | (3.06) |
| Jun 2026 | 53.1% | 0.87 |
| Mar 2026 | 52.3% | 2.45 |
| Dec 2025 | 49.8% | (2.79) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| GKOS Glaukos Corporation compare | 81.1% |
| PODD Insulet Corporation compare | 71.9% |
| SNN Smith & Nephew SNATS, Inc. compare | 70.5% |
| TXG 10x Genomics compare | 70.0% |
| GMED Globus Medical, Inc. compare | 69.1% |
| PEN Penumbra, Inc. compare | 68.0% |
| BIO.B Bio-Rad Laboratories, Inc. | 51.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 51.3% |
| BRKR Bruker Corporation compare | 47.7% |
| Medical Devices industry median | 57.8% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on BIO.B
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement